• 6 min read
• Published on 3 August 2025
Listen to article
6:46Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
I’ve always been a bit sceptical of a ‘free lunch’, and it seems Washington has finally caught on. For decades, the world’s pharmaceutical giants have enjoyed a rather cushy arrangement. They develop a new wonder drug, sell it for a reasonable price in places like Germany or France, and then charge an eye-watering premium to patients in the United States. It’s been the industry’s golden goose, a seemingly endless source of cash that has propped up share prices and funded lavish R&D departments. But now, it looks like the party might be coming to an end.
A presidential directive has landed on the desks of 17 of the biggest names in the business, and its message is brutally simple. Cut your US prices, or else. This isn't just political theatre, it's a direct assault on the industry's most cherished business model.
The weapon of choice here is something called the ‘Most-Favoured-Nation’ standard. It sounds terribly official, but the concept is one any savvy shopper would understand. Why should you pay more for the same product than your neighbour? The directive essentially says that drug companies must offer American patients the lowest price they charge in any other developed country.
Let’s put that into perspective. Imagine a life-saving treatment costs, say, £3,000 a month in the UK, a price negotiated by the NHS. The very same pill, from the same factory, might be sold for £8,000 a month in America. Under this new proposal, the US price would have to drop to the UK level. You don’t need to be a financial wizard to see what that does to a company’s profit margins. For firms that have built their empires on the back of American premium pricing, this is nothing short of a revolution.
The list of companies in the firing line reads like a who’s who of the pharmaceutical world. Pfizer, Merck, and Eli Lilly are just a few of the titans being called to account. These aren't minnows, they are the architects of the current system, and their business models are now under intense scrutiny.
For an investor, this throws up some rather pointed questions. How much of a company’s current valuation is based on the assumption that the American gravy train will run forever? Which firms are nimble enough to adapt, and which are too reliant on the old ways? The uncertainty is already causing ripples in the market, as investors try to figure out who is most exposed. To me, this isn't just a one-off event, it's a fundamental shift. The entire theme of Pharma's Pricing Pressure is now a central question for any serious healthcare investor.
Navigating this new landscape requires a steady hand. The immediate reaction is, of course, volatility. But beneath the noise, there are strategic considerations. Companies with genuinely innovative pipelines and a diverse global footprint may prove more resilient. If you have a drug that truly changes lives and has no alternative, you might still hold some pricing power. Those relying on older, less unique treatments could find themselves in a much tougher spot.
Of course, all investing carries risk, and this situation is dripping with it. The political winds could change, and the industry will no doubt deploy its army of lobbyists to fight back. However, the direction of travel seems clear. The days of unquestioned price setting in the world’s largest healthcare market may be numbered. The game is changing, and for investors, the challenge is to look past the headlines and identify the companies built for this new, tougher reality. The demand for medicine isn't going away, but the way it's paid for just might.
View the full Basket:Pharma's Pricing Pressure
View the full Basket:Pharma's Pricing Pressure
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article